COMPOUND RECORD / SELANK

SelankСеланк

StressCognition

Source linked

What the studies found

Randomized study in people · 2008

Anxiety improvements reported against an active comparator

Anxiety outcome: Similar changes reportedNo numerical scale change supplied

In a 62-patient report, the authors described similar anxiety changes with Selank and the comparator treatment, alongside measurements of enkephalin metabolism.

Study notes · methods, sources and limitations

Participants or model 62 patients; treatment-arm counts conflict between indexed abstract (30/32) and abridged reprint (42/20)

Design 62 patients with generalized anxiety disorder or neurasthenia. Indexed abstract: Selank 30, medazepam 32.

Treatment-arm counts in an abridged reprint: 42 and 20Conflicts with the indexed 30/32 split

Important limitations

Treatment-group counts differ between sources; the original report is needed to resolve them.
Original journal version needed to resolve treatment-arm discrepancy. The 30 anxiety and 32 neurasthenia cases are diagnostic groups. Treatment-group sizes are separate. Allocation concealment and blinding remain unresolved. Active-comparator similarity does not establish noninferiority or long-term safety.
The arm discrepancy is unresolved. The figures describe diagnostic groups. Treatment-group sizes are separate.

Zh Nevrol Psikhiatr Im S S Korsakova. 108(4):38–48 · Journal publication

Original source or citation ↗

Study results and tables ↗

Animal research · 2013

Selank in rat and primate fatigue models

Rats: The abstract reports a short-lived change in fatigue-like behavior after Selank.
Primates: The authors reported a gradual increase in task performance and changes in EEG after repeated intranasal dosing.

The abstract reports a short-lived change in fatigue-like behavior after Selank.

Study notes · methods, sources and limitations

Participants or model Rats and monkeys exposed to experimental stressors

Design Conference abstract describing behavioral, EEG, autonomic and motor assessments in an experimental fatigue model. Monkeys received repeated intranasal Selank. The abstract supplies no dose, group sizes or effect estimates.

Important limitations

The authors modeled selected fatigue-like features in animals. The experiment did not enroll people or validate an ME/CFS model.

6th Russian Symposium on Proteins and Peptides, p. 106 · Publication record

Original source or citation ↗

Study results and tables ↗

Comparison in people · 2014

A comparison of the anxiolytic effect and tolerability of Selank and phenazepam in anxiety disorders

Persistence of anxiolytic effect: One week after the final doseAbsolute change and confidence interval absent from the abstract

An active-comparator report describes anxiety and quality-of-life changes.

Study notes · methods, sources and limitations

Participants or model 60 patients with anxiety/phobic or somatoform disorders

Design 60 patients with anxiety/phobic or somatoform disorders; Selank versus phenazepam.

Important limitations

Random allocation and blinding are not established from the abstract. Short follow-up and a small comparison cannot establish long-term safety or general cognitive enhancement.
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.

Zh Nevrol Psikhiatr Im S S Korsakova. 114(7):17–22 · Journal publication

Original source or citation ↗

Study results and tables ↗

01 / OVERVIEW

About Selank

Names in this research collection

TP-7 · TKPRPGP

A synthetic peptide analogue of tuftsin, a naturally occurring immune-related peptide. Selank has been investigated in anxiety-related and neurobiological research.

Identity / background source ↗

Research background

Tuftsin-derived peptide investigated in anxiety comparisons, stress models and neurochemical assays. Its clinical and laboratory evidence are kept distinct from unverified archival claims.

Autoimmune research: disease-specific findings, immune effects and open questions ↗

Russian ME/CFS and fatigue research ↗

Pregnancy and offspring research

Selank given to adult offspring increased sensory attention by a reported factor of 2–3 and facilitated learning 1.5-fold (both p<0.01). This was treatment after prenatal injury, not administration to pregnant mothers.

Adult offspring treatment cannot establish fetal safety of maternal Selank.

Reported findings and methods ↗ · Pregnancy research: full evidence review and archive ↗

More study findings

Animal research · 2011

Semax and Selank in acute loaded swimming

Study of multiple preparations

30 minutes: Semax +45%; Selank +50%Reported relative to control.
Four hours: Semax +110%; Selank +45%The treated groups were distinct.
24 hours: No detected benefit with either peptideThe separate human physiology comparison included 36 participants and did not test either peptide.

Both peptides prolonged swimming at selected early time points. Neither had a reported effect at 24 hours.

Study notes · methods, sources and limitations

Participants or model Rat subgroups of 6–7 per sampling interval. The separate human physiology comparison included 18 athletes and 18 comparison participants without a drug intervention.

Design Forced swim with 20% body-mass load, tested 0.5, 4 or 24 hours after administration. Separate enzyme and biochemical measurements.

Reported study exposure: Single intranasal Semax or Selank, 300 µg/kg, 1% solution, 6 µL. Control received distilled water.

Important limitations

Small subgroups, incomplete uncertainty and extreme swim conditions.

Doctoral dissertation author abstract, methods and animal results · Doctoral dissertation author abstract, methods and animal results

Original source or citation ↗

Study results and tables ↗

Animal research · 2009

Rat behavioral assays: selank

Study of multiple preparations

Noopept, Semax, Selank and Dilept · vertical activity: Reduced vertical movements reportedCompound-specific rat behavior at the stated doses, not a measure of human alertness.
Porsolt immobility: Lower with Oleyl-Cortagen, Dilept and Cortexin; higher with Cerebrolysin, Semax, Cortagen and SelankThis unweighted behavior assay is distinct from loaded endurance swimming. Piracetam was inactive in the report.

Separate comparisons in an assay battery.

Study notes · methods, sources and limitations

Participants or model 192 Wistar rats, 200–220 g; methods describe at least 10–12 per group across a behavioral test battery

Design 192 Wistar rats, 200–220 g; methods describe at least 10–12 per group across a behavioral test battery

Reported study exposure: 0.1 mg/kg intraperitoneally in the rat study.

Important limitations

Electrical self-stimulation and immobility do not measure athletic endurance.
Multiple behavioral comparisons, endpoint-specific group sizes and precise uncertainties need table recovery. Deltaran is the tested DSIP-containing formulation; no result for isolated DSIP can be inferred. The 2015 dissertation used separate doses/routes; it is not confirmed as independent replication of every experiment.
Opposing effects across assays are informative. Electrical self-stimulation and immobility are behavior readouts, and neither establishes improved human motivation or endurance.

Medical Academic Journal, 2009; publisher article 9357 · Original journal article

Original source or citation ↗

Study results and tables ↗

Animal research · 2008

Use of Selank to correct measures of integrative brain activity and biogenic amine levels in adult rats resulting from antenatal hypoxia

Sensory attention: Reported 2–3-fold increasep<0.01; no n or confidence interval supplied
Learning: Reported 1.5-fold facilitationp<0.01
Monoamine balance: Investigative behavior and serotonin/noradrenaline balance reportedly restored; exact concentrations absent

Study notes · methods, sources and limitations

Participants or model Adult rats exposed to antenatal hypoxia on gestation days 14–16; n not supplied in abstract

Design Adult-offspring behavioral and brain serotonin/noradrenaline assessment after prenatal hypoxia; Selank 300 µg/kg intraperitoneally.

Important limitations

Adult offspring treatment cannot establish fetal safety of maternal Selank.
Adult offspring treatment cannot establish fetal safety of maternal Selank. The 2008 English article translates the 2006 Russian paper, PMID 17385425; these are not independent replications. Sample sizes, blinding, litter handling and numerical raw scores are unavailable in the abstract.

Neuroscience and behavioral physiology. 2008;38(2):203. PMID 18197389 · Original journal publication

Original source or citation ↗

Study results and tables ↗

Lab research · 2017

Studying the Toxic Effects of Some Biologically Active Peptides on the Model of Mouse Embryonic Stem Cells

Study of multiple preparations

Selank neuronal differentiation: GABA-positive neuron ratio decreased by 61%Selank 100 µM versus control; not an in-vivo malformation endpoint
PGP proliferation: Small but significant inhibition at 10 µMNo numerical inhibition magnitude in abstract
Semax cell survival: Increased survival at 10 and 0.1 µM during serum deprivationCell-stress endpoint, not reproductive toxicology

Selank at 100 µM reduced the GABA-positive neuron ratio by 61% versus control. Semax improved cell survival under serum deprivation, while PGP modestly inhibited proliferation at 10 µM. Cell findings cannot substantiate the abstract’s broad fetal-safety conclusion.

More reported outcomes

Safety-inference limit: The authors infer no embryonic/fetal toxicity; this culture model does not establish that claim in pregnancy

Study notes · methods, sources and limitations

Participants or model Mouse embryonic stem cells and neuronal derivatives, not pregnant animals or human fetuses

Design Cultured mouse embryonic stem cells; proliferation, survival during serum deprivation and neuronal differentiation after several peptides and growth-factor controls.

Important limitations

Embryonic-cell experiments do not test placental exposure, whole-embryo development, birth defects or pregnancy outcomes.
Embryonic-cell experiments do not test placental exposure, whole-embryo development, birth defects or pregnancy outcomes. The study also found reduced cell differentiation and proliferation. Concentrations in a culture dish are not human doses; biological replicate counts and complete numerical results absent from the abstract.

Bulletin of experimental biology and medicine. 2017;163(6):731. PMID 29063333 · Original journal publication

Original source or citation ↗

Study results and tables ↗

Comparison in people · 2015

Optimization of the treatment of anxiety disorders with selank

Anxiety improvement: Earlier with add-on SelankNo numerical magnitude reported
Sedation and other adverse symptoms: Fewer reported with the combinationEvent counts not supplied

The authors report earlier symptom improvement and fewer unwanted effects with adjunctive Selank. Both groups received phenazepam.

Study notes · methods, sources and limitations

Participants or model 70 patients: 40 Selank plus phenazepam; 30 phenazepam alone

Design 70 patients: phenazepam alone 30 versus phenazepam plus Selank 40.

Important limitations

Does not isolate Selank monotherapy. Allocation and blinding unresolved; a combination comparison is not general evidence of safety.
Both groups received phenazepam. This comparison does not isolate Selank monotherapy.

Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(6):33–40 · Indexed abstract

Original source or citation ↗

Study results and tables ↗

Animal research · 2022

Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats.

Total withdrawal index reduction: 39.6% Selank versus 49.3% diazepam
Tactile sensitivity threshold: Ninefold versus thirteenfold increase
Convulsions, ptosis and posture disorders: Attenuation reported with Selankp<0.0001

Selank reduced the overall withdrawal score by 39.6%, compared with 49.3% for diazepam. It also reduced several physical withdrawal signs. This is an animal-model finding, not a clinical withdrawal treatment.

Study notes · methods, sources and limitations

Participants or model Rats with naloxone-triggered morphine withdrawal

Design Rat morphine-withdrawal model; single IP Selank 0.3 mg/kg versus diazepam 2 mg/kg.

Important limitations

Animal and laboratory findings do not establish benefit in people. Abstract only. Full methods, sample-size details and adverse-event tables were outside the review.
Animal dependence model; no human withdrawal regimen or efficacy is established.

Bulletin of experimental biology and medicine · Indexed abstract

Original source or citation ↗

Study results and tables ↗

Animal research · 2020

Morphological Changes in the Large Intestine of Rats Subjected to Chronic Restraint Stress and Treated with Selank.

Corticosterone and colon-wall injury: Reductions reportedNo numerical concentration, injury score or sample size supplied

Selank-treated rats had lower corticosterone and fewer stress-related changes in the colon wall. The study connects stress biology with tissue changes in the gut.

Study notes · methods, sources and limitations

Participants or model Male Wistar rats exposed to restraint stress

Design Male Wistar rats with restraint stress; IP Selank 80, 250 or 750 micrograms/kg 15 minutes before exposure.

Important limitations

Animal and laboratory findings do not establish benefit in people. Abstract only. Full methods, sample-size details and adverse-event tables were outside the review.
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.

Bulletin of experimental biology and medicine · Indexed abstract

Original source or citation ↗

Study results and tables ↗

Animal research · 2019

Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats.

Object recognition in non-ethanol nine-month-old rats: Improvement reportedp<0.05
Ethanol-withdrawal memory/attention disturbances: Prevention reportedp<0.01
Ethanol-associated BDNF increase: Prevented in hippocampus and frontal cortexp<0.05

Selank improved object-recognition performance during alcohol withdrawal and prevented the ethanol-associated rise in BDNF in the hippocampus and frontal cortex. This finding concerns normalization in this model, not a general increase in BDNF.

Study notes · methods, sources and limitations

Participants or model Rats exposed to 10% ethanol as their only fluid for 30 weeks

Design Rats exposed to 10% ethanol as sole fluid for 30 weeks; Selank 0.3 mg/kg/day IP for seven days. Object-recognition test and ex-vivo BDNF assays.

Important limitations

Animal and laboratory findings do not establish benefit in people. Abstract only. Full methods, sample-size details and adverse-event tables were outside the review.
No numerical behavioral effect size is supplied. This is normalization of an ethanol-associated BDNF increase, not a claim that Selank universally raises BDNF.

Bulletin of experimental biology and medicine · Indexed abstract

Original source or citation ↗

Study results and tables ↗

Animal research · 2019

Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress.

Degenerative liver changes: Reduced at all three doses
Nucleus/cytoplasm ratio: Restored at 300 and 1,000 micrograms/kg
Strongest reported stress-limiting effect: 300 micrograms/kgMiddle tested dose; no numerical histology effect size supplied

Selank reduced stress-related liver-cell damage at all tested doses. The strongest reported effect occurred at the middle dose, 300 micrograms/kg; the response was not simply greater at higher doses.

Study notes · methods, sources and limitations

Participants or model Male Wistar rats under chronic foot-shock stress

Design Male Wistar rats with foot-shock stress; IP Selank 100, 300 or 1,000 micrograms/kg 15 minutes before each session.

Important limitations

Animal and laboratory findings do not establish benefit in people. Abstract only. Full methods, sample-size details and adverse-event tables were outside the review.
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.

Bulletin of experimental biology and medicine · Indexed abstract

Original source or citation ↗

Study results and tables ↗

Animal research · 2019

State of Colon Microbiota in Rats during Chronic Restraint Stress and Selank Treatment.

Gut microbiota: Restoration reportedNo bacterial abundance percentages or species-level effect sizes in the abstract

Stress shifted the balance of intestinal bacteria. The authors report that Selank restored the microbiota toward its usual composition; the abstract does not provide species-level changes or numerical effect sizes.

Study notes · methods, sources and limitations

Participants or model Male Wistar rats under chronic restraint stress

Design Male Wistar rats with chronic restraint stress; IP Selank 80, 250 or 750 micrograms/kg 15 minutes before exposure.

Important limitations

Animal and laboratory findings do not establish benefit in people. Abstract only. Full methods, sample-size details and adverse-event tables were outside the review.
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.

Bulletin of experimental biology and medicine · Indexed abstract

Original source or citation ↗

Study results and tables ↗

Research updates ↗

Compound class: Synthetic regulatory neuropeptide
Research collection: Neuropeptide research · editorial grouping
Research institutions: No institutional affiliation recorded
Source review: Review dates and the material assessed are listed with each publication below.

02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research Small active-comparator anxiety studies and imaging
Study methods Study-specific design and limitations below
Independent replication Independent replication and participant overlap are unclear
Source access Indexed abstracts, selected publisher text and archival records
Safety evidence Long-term safety and product equivalence not established by this collection

Open a topic for the evidence assessment.

More findings, background and history

RELATED PEPTIDE RESEARCH / UPDATED OCTOBER 2026

Connections in the research

The glyprolin literature places Selank in a hybrid-peptide design tradition. That history does not transfer findings between Selank, Semax and isolated PGP.

Glyprolins & PGP hybrids ↗

A family record separating simple Pro/Gly peptides, PGP-containing hybrids and proposed protein-fragment lineages.

View the peptide family map and sources ↗

What remains unclear

The 2008 abstract and abridged reprint give different treatment-arm sizes, 30 and 32 versus 42 and 20. The methods of the 2025 psychosomatic-symptom study remain unavailable.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗

SOURCE REVIEW / 2 OCTOBER 2026

Additional clinical comparison and source discrepancy added

The 70-patient adjunctive phenazepam report is linked. The shortened 2008 reprint conflicts with the indexed abstract on treatment-arm sizes.

What remains unresolved

Obtain the unabridged 2008 journal paper; resolve group sizes, blinding and allocation. Similarity to medazepam does not establish equivalence.

Source 1 ↗Source 2 ↗

Compare all 13 evidence updates ↗

REGULATORY NEUROPEPTIDES / SOURCE CHECK 30 SEP 2026

Selank: from tuftsin to stress research.

Selank is Thr–Lys–Pro–Arg–Pro–Gly–Pro (TKPRPGP): the tuftsin sequence followed by Pro–Gly–Pro. The published development account links the Institute of Molecular Genetics and Zakusov pharmacology institute. Identity source ↗

Educational only; not medical advice. Seek qualified healthcare help for any condition. Evidence here concerns the preparations studied; it is not automatically applicable to N-acetylated or amidated products, other routes, or self-combined stacks.

Clinical anxiety comparisons

The 62-patient medazepam comparison and 60-patient phenazepam comparison are linked with their design limits. Similar reported outcomes do not by themselves establish equivalence, long-term safety or absence of dependence.

Source 1 ↗Source 2 ↗

Stress and tuftsin-family research

Animal conflict-stress experiments compare related peptides and fragments. The 2002 Russian citation and 2003 English record are not treated as independent replications.

Source 1 ↗Source 2 ↗Source 3 ↗

Enkephalin, GABA and neurotrophins

Human-serum assays, isolated-membrane work and rat gene-expression studies address different mechanisms. Human biological material is not the same as a human treatment trial.

Source 1 ↗Source 2 ↗Source 3 ↗Source 4 ↗

Imaging and open research branches

The shared imaging paper compares separate Semax, Selank and placebo conditions—not a combined stack. Brain/spleen and anti-ulcer dissertation leads remain visible without importing unverified outcomes.

Source 1 ↗Source 2 ↗Source 3 ↗Source 4 ↗

Lineage and document recovery

Bibliographic records, patents and dissertations provide historical context. An available file is not a completed evidence review. Unverified military-origin claims and numerical duration claims have not been adopted.

2018 / Library record · full text listed as open

Selank as a modulator of GABAergic, neuroreception and signaling gene expression

Catalogue identity checked. Dissertation findings and overlap with journal publications remain to be appraised.

Bibliographic record ↗

2008 / Indexed record · no abstract available

Intranasal Selank and hippocampal BDNF expression in rats

Animal neurotrophin research; record and title checked. No effect magnitude entered without original results.

Bibliographic record ↗

2016 / Publisher full text / PDF

Selank GABA-related gene-expression paper — publisher PDF

Alternate access to study ss-26924987; the same paper, not another experiment.

Bibliographic record & PDF ↗

1989 / Unverified archival citation

Early tuftsin-analogue / Selank precursor work

Exact source remains unidentified; no definitive Selank discovery date inferred.

Bibliographic record ↗

1995 / Unverified archival citation

Serotonergic contribution to synthetic-tuftsin-analogue anxiolysis

Original record and journal metadata require verification.

Bibliographic record ↗

2012 / Unverified archival citation

Selank gene expression in brain and spleen

An unverified citation describes a 160-page dissertation; catalogue and original text remain recovery targets.

Bibliographic record ↗

Date unresolved / Unverified archival citation

Anti-ulcer effects of Selank and its fragments

This citation concerns gastrointestinal cytoprotection and peptide fragments. Clinical effects on ulcers remain uncertain.

Bibliographic record ↗

Date unresolved / Unverified archival citation

Clinical pharmacology of Selank — dissertation lead

Exact dissertation identity and overlap with clinical publications require verification.

Bibliographic record ↗

Explore Semax ↗ Compare the distinct tissue-peptide tradition ↗

PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 4 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2026 · EP4758157A1 · 2026 European publication: modified GHK, Epitalon, Semax, Selank and Cortagen analoguesModified analogue · Reported cell-number multiples versus control: GHK 260-fold, GHK-Cu 320-fold, Ac-GHK-Arg-NH2 360-fold

Reported findings

The disclosure reports cell-growth, telomerase-related and stability findings for chemically modified peptides, with several ambiguities in reporting.

GHK-related long-term keratinocyte assay: Reported cell-number multiples versus control: GHK 260-fold, GHK-Cu 320-fold, Ac-GHK-Arg-NH2 360-foldAs stated in the patent; assay normalization and duration are insufficiently clear for clinical interpretation
Epithalon-related laboratory summary: 41.2% for modified peptide versus 33.3% for parentThe text combines telomerase activity and telomere elongation rather than clearly separating the endpoints

All reported results, comparisons and limitations →

Modified analogue. The family claims chemically modified peptides, including acetylated parent sequences extended with C-terminal arginine amide; it also has a 2025 WO publication.

Ac-GHK-Arg-NH2 and the corresponding modified AEDG, Semax, Selank and Cortagen constructs are different molecules from their parents. The EP and WO publications are one family, not independent studies.

Publication: EP4758157A1 ↗ · 2026-06-17
Earliest priority / filing: 2023-08-13 / 2023-08-13
Original applicant / assignee: Individual
Indexed status: Pending · checked 2026-11-06
Patent family: 88092996 · family publications are related filings, not independent studies.

Original title, inventors and related publications

New peptides and use thereof

Inventors: Filip Majewski.

EP4758157A1 · WO2025037992A1

Read source review →

2025 · RU2833679C1 · Selank: 2025 pancreatic-injury patentUse · Purulent inflammatory changes were absent in the treated tissue examples; stromal inflammatory proliferation and islet sclerosis were reduced

Narrative findings; numerical extraction incomplete

The patent describes less pancreatic inflammation and structural damage during Selank treatment.

Histology: Purulent inflammatory changes were absent in the treated tissue examples; stromal inflammatory proliferation and islet sclerosis were reducedRat toxic-injury models; numerical histological scores not transcribed
Islet preservation: Islet-area preservation described with both administration routesThe narrative describes similar effects; no formal equivalence analysis established

All reported results, comparisons and limitations →

Use. The patent proposes Selank in toxic pancreatic-injury research with animal-model support.

Toxic injury in rats does not establish treatment of diabetes, autoimmune pancreatitis or human pancreatic disease.

Publication: RU2833679C1 ↗ · 2025-01-28
Earliest priority / filing: Not established / 2023-09-15
Original applicant / assignee: Акционерное общество "Инновационный научно-производственный центр "Пептоген"
Indexed status: Not shown; official status unverified · checked 2026-11-06
Patent family: Grouping identifier unavailable · family publications are related filings, not independent studies.

Original title, inventors and related publications

Use of thr-lys-pro-arg-pro-gly-pro peptide for protection of insular pancreas and exocrine section thereof from toxic destructive effects

Inventors: Николай Алексеевич Смирнов; Александр Леонидович Хохлов; Елена Игоревна Самарина; Сергей Владимирович Куликов; Владимир Николаевич Федоров; Татьяна Алимовна Зубова.

RU2833679C1

Original patent PDF ↗

Read source review →

2019 · RU2709534C1 · Selank: adjunctive chronic-dermatosis methodUse · PASI 13 → 1; Beck depression 12 → 5; Hamilton anxiety 17 → 7

Reported findings

The patent reports reductions in skin-severity and psychological scores, alongside standard topical treatment.

Psoriasis case: PASI 13 → 1; Beck depression 12 → 5; Hamilton anxiety 17 → 7Skin findings described through day 15Single-patient before/after findings
Eczema case: EASI 9 → 1; Beck depression 11 → 4Skin findings described through day 16Single-patient before/after findings

All reported results, comparisons and limitations →

Use. The filing proposes Selank alongside care for chronic dermatoses.

Concurrent care prevents simple attribution; the document also contains a dose-unit inconsistency, so no administration regimen is reproduced here.

Publication: RU2709534C1 ↗ · 2019-12-18
Earliest priority / filing: 2018-07-12 / 2018-07-12
Original applicant / assignee: Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России)
Indexed status: Not shown; official status unverified · checked 2026-11-06
Patent family: 69006604 · family publications are related filings, not independent studies.

Original title, inventors and related publications

Method of treating chronic dermatoses

Inventors: Луиза Афгатовна Юсупова; Евгения Владимировна Бильдюк.

RU2709534C1

Original patent PDF ↗

Read source review →

2019 · RU2709503C1 · RU2709503C1: Selank in acute cold-water hypothermia modelsUse · 23% longer active swimming than saline

Reported findings

Applicant claims use of Selank for resistance to acute cooling, with separate rat swimming and survival examples.

Free swimming · Example 1: 23% longer active swimming than saline10 rats per arm at 9°C; reported p<0.05.
Post-exposure arm · Example 2: 40% survived the subsequent observation periodOnly 25% of saline controls survived the first hour and all died by day 2. Patent reports a 3.2-fold first-hour survival comparison.

All reported results, comparisons and limitations →

Use. Applicant claims use of Selank for resistance to acute cooling, with separate rat swimming and survival examples.

Animal patent experiments. Human treatment of hypothermia is outside the evidence.

Publication: RU2709503C1 ↗ · 2019-12-18
Earliest priority / filing: 2019-05-23 / 2019-05-23
Original applicant / assignee: Not established from accessed metadata
Indexed status: Not shown; official status unverified · checked 2026-11-09
Patent family: 69006996 · family publications are related filings, not independent studies.

Original title, inventors and related publications

Применение пептида Thr-Lys-Pro-Arg-Pro-Gly-Pro (селанк) для повышения резистентности организма к острой гипотермии

Inventors: L. A. Andreeva; V. P. Vdovichenko; E. A. Nemersky; A. Yu. Petrovskaya; A. K. Petrovsky; N. A. Smirnov; V. N. Fedorov; T. B. Fedorova.

RU2709503C1

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Linked sources

Explore the research map and unresolved leads ↗

2011 · Semax and Selank in acute loaded swimming30 minutes: Semax +45%; Selank +50%

2011Animal / experimentalRussian source · see review scope

Semax and Selank in acute loaded swimming

· Doctoral dissertation author abstract, methods and animal results

Format: Doctoral dissertation author abstract, methods and animal results · Reviewed: Reported methods, results and evidence limitations

V. B. Solovyov · Doctoral dissertation author abstract, methods and animal results

Both peptides prolonged swimming at selected early time points. Neither had a reported effect at 24 hours.

Results and tables

Reported findings and study design

Both peptides prolonged swimming at selected early time points. Neither had a reported effect at 24 hours.

Forced swim with 20% body-mass load, tested 0.5, 4 or 24 hours after administration. Separate enzyme and biochemical measurements.

Dose, route and schedule

Single intranasal Semax or Selank, 300 µg/kg, 1% solution, 6 µL. Control received distilled water.

Protocol source ↗ · Doctoral dissertation author abstract, methods and animal results

Results · Doctoral dissertation author abstract, methods and animal results
Measure	Result	Comparison, timing and statistics
30 minutes	Semax +45%; Selank +50%	Reported relative to control.
Four hours	Semax +110%; Selank +45%	The treated groups were distinct.
24 hours	No detected benefit with either peptide	The separate human physiology comparison included 36 participants and did not test either peptide.

Small subgroups, incomplete uncertainty and extreme swim conditions.

Source for these results ↗ · Reviewed 2026-11-09

Population / setting: Rat subgroups of 6–7 per sampling interval. The separate human physiology comparison included 18 athletes and 18 comparison participants without a drug intervention.
Source reviewed: Doctoral dissertation author abstract, methods and animal results

Study limitations

Small subgroups, incomplete uncertainty and extreme swim conditions.

Reviewed 2026-11-09.

Read the source ↗

2009 · Shabanov’s rat peptide behavior comparison: Oleyl-Cortagen and CortexinNoopept, Semax, Selank and Dilept · vertical activity: Reduced vertical movements reported

2009Animal / experimentalFull text available

Shabanov’s rat peptide behavior comparison: Oleyl-Cortagen and Cortexin

· Original journal article

Format: Publisher full-text methods and results narrative; original PDF tables not recovered · Reviewed: Reported methods, results and evidence limitations

P. D. Shabanov et al. · Medical Academic Journal, 2009; publisher article 9357

Oleyl-Cortagen and Cortexin increased hypothalamic self-stimulation by 32% and 23%, respectively. Cortagen and Cerebrolysin did not change this outcome; other behavioral assays differed.

Results and tables

Reported findings and study design

Oleyl-Cortagen and Cortexin increased hypothalamic self-stimulation by 32% and 23%, respectively. Cortagen and Cerebrolysin did not change this outcome; other behavioral assays differed.

192 Wistar rats, 200–220 g; methods describe at least 10–12 per group across a behavioral test battery

Dose, route and schedule

Intraperitoneal doses: 1 mg/kg Cortexin, Cerebrolysin, Cortagen, Oleyl-Cortagen, Noopept and Dilept; 0.1 mg/kg Deltaran, Semax and Selank; piracetam 200 mg/kg. General behavior tests 30–40 minutes post-dose; self-stimulation measured 15–20 minutes post-dose.

Protocol source ↗ · Publisher full-text methods and results narrative; original PDF tables not recovered

Results · Publisher full-text methods and results narrative; original PDF tables not recovered
Measure	Result	Comparison, timing and statistics
Oleyl-Cortagen · self-stimulation	+32% in lateral-hypothalamic pedal presses	Reported relative increase, not an endurance or strength endpoint.
Cortexin · self-stimulation	+23% in lateral-hypothalamic pedal presses	Reported relative increase; no direct statistical test versus Oleyl-Cortagen supplied in narrative.
Cortagen and Cerebrolysin · self-stimulation	No change reported in pedal-press frequency	At the systemic doses in this article; does not contradict the separate central-dose comparisons.
Open-field behavior	Oleyl-Cortagen increased horizontal and vertical movement but halved hole exploration	Cortexin and Cerebrolysin increased horizontal movement; Dilept reduced horizontal and vertical movement.
Noopept, Semax, Selank and Dilept · vertical activity	Reduced vertical movements reported	Compound-specific rat behavior at the stated doses, not a measure of human alertness.
Porsolt immobility	Lower with Oleyl-Cortagen, Dilept and Cortexin; higher with Cerebrolysin, Semax, Cortagen and Selank	This unweighted behavior assay is distinct from loaded endurance swimming. Piracetam was inactive in the report.
Deltaran · grooming	Grooming reactions increased	The report tested Deltaran, a DSIP-containing formulation; this observation is not assigned to isolated DSIP.

Opposing effects across assays are informative. Electrical self-stimulation and immobility are behavior readouts, and neither establishes improved human motivation or endurance.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting: 192 Wistar rats, 200–220 g; methods describe at least 10–12 per group across a behavioral test battery
Source reviewed: Publisher full-text methods and results narrative; original PDF tables not recovered

Study limitations

Multiple behavioral comparisons, endpoint-specific group sizes and precise uncertainties need table recovery.
Deltaran is the tested DSIP-containing formulation; no result for isolated DSIP can be inferred.
The 2015 dissertation used separate doses/routes; it is not confirmed as independent replication of every experiment.

Reviewed 2026-11-08.

Read the source ↗

2008 · Use of Selank to correct measures of integrative brain activity and biogenic amine levels in adult rats resulting from antenatal hypoxiaSensory attention: Reported 2–3-fold increase

2008Animal / experimentalEnglish abstract

Use of Selank to correct measures of integrative brain activity and biogenic amine levels in adult rats resulting from antenatal hypoxia

selank · Original journal publication

Format: Publication record and available text · Reviewed: Indexed original abstract; full methods and outcome tables not recovered

Semenova TP, Kozlovskaya MM, Zuikov AV, Kozlovskii II, Zakharova NM, Andreeva LA · Neuroscience and behavioral physiology. 2008;38(2):203. PMID 18197389

Results and tables

Reported findings and study design

Reported findings

Adult-offspring behavioral and brain serotonin/noradrenaline assessment after prenatal hypoxia; Selank 300 µg/kg intraperitoneally.

Results · Indexed original abstract; full methods and outcome tables not recovered
Measure	Result	Comparison, timing and statistics
Sensory attention	Reported 2–3-fold increase	p<0.01; no n or confidence interval supplied
Learning	Reported 1.5-fold facilitation	p<0.01
Monoamine balance	Investigative behavior and serotonin/noradrenaline balance reportedly restored; exact concentrations absent

Adult offspring treatment cannot establish fetal safety of maternal Selank. The 2008 English article translates the 2006 Russian paper, PMID 17385425; these are not independent replications. Sample sizes, blinding, litter handling and numerical raw scores are unavailable in the abstract.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting: Adult rats exposed to antenatal hypoxia on gestation days 14–16; n not supplied in abstract
Source reviewed: Indexed original abstract; full methods and outcome tables not recovered

Study limitations

Adult offspring treatment cannot establish fetal safety of maternal Selank.
The 2008 English article translates the 2006 Russian paper, PMID 17385425; these are not independent replications.
Sample sizes, blinding, litter handling and numerical raw scores are unavailable in the abstract.

Reviewed 2026-11-08.

Read the source ↗

2017 · Studying the Toxic Effects of Some Biologically Active Peptides on the Model of Mouse Embryonic Stem CellsSelank neuronal differentiation: GABA-positive neuron ratio decreased by 61%

2017In vitroEnglish abstract

Studying the Toxic Effects of Some Biologically Active Peptides on the Model of Mouse Embryonic Stem Cells

semax, selank, glyprolins · Original journal publication

Format: Publication record and available text · Reviewed: Indexed original abstract; full methods and outcome tables not recovered

Kobylyanskii AG, Zolotarev YA, Andreeva LA, Grivennikov IA, Myasoedov NF · Bulletin of experimental biology and medicine. 2017;163(6):731. PMID 29063333

Results and tables

Reported findings and study design

Reported findings

Cultured mouse embryonic stem cells; proliferation, survival during serum deprivation and neuronal differentiation after several peptides and growth-factor controls.

Results · Indexed original abstract; full methods and outcome tables not recovered
Measure	Result	Comparison, timing and statistics
Selank neuronal differentiation	GABA-positive neuron ratio decreased by 61%	Selank 100 µM versus control; not an in-vivo malformation endpoint
PGP proliferation	Small but significant inhibition at 10 µM	No numerical inhibition magnitude in abstract
Semax cell survival	Increased survival at 10 and 0.1 µM during serum deprivation	Cell-stress endpoint, not reproductive toxicology
Safety-inference limit	The authors infer no embryonic/fetal toxicity; this culture model does not establish that claim in pregnancy

Embryonic-cell experiments do not test placental exposure, whole-embryo development, birth defects or pregnancy outcomes. The study also found reduced cell differentiation and proliferation. Concentrations in a culture dish are not human doses; biological replicate counts and complete numerical results absent from the abstract.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting: Mouse embryonic stem cells and neuronal derivatives, not pregnant animals or human fetuses
Source reviewed: Indexed original abstract; full methods and outcome tables not recovered

Study limitations

Embryonic-cell experiments do not test placental exposure, whole-embryo development, birth defects or pregnancy outcomes.
The study also found reduced cell differentiation and proliferation.
Concentrations in a culture dish are not human doses; biological replicate counts and complete numerical results absent from the abstract.

Reviewed 2026-11-08.

Read the source ↗

2026 · 2026 European publication: modified GHK, Epitalon, Semax, Selank and Cortagen analogues — EP4758157A1GHK-related long-term keratinocyte assay: Reported cell-number multiples versus control: GHK 260-fold, GHK-Cu 320-fold, Ac-GHK-Arg-NH2 360-fold

2026Patent / reported experimentsFull text available

2026 European publication: modified GHK, Epitalon, Semax, Selank and Cortagen analogues — EP4758157A1

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Filip Majewski · EP4758157A1 · patent family 88092996

The disclosure reports cell-growth, telomerase-related and stability findings for chemically modified peptides, with several ambiguities in reporting.

Results and tables

Reported patent results

Reported findings

The disclosure reports cell-growth, telomerase-related and stability findings for chemically modified peptides, with several ambiguities in reporting.

Patent laboratory comparisons of modified versus parent peptides; no verified human treatment cohort.

Results · Experimental Examples 2.2–2.6 and Example 3; cell, telomerase and stability narratives.
Measure	Result	Comparison, timing and statistics
GHK-related long-term keratinocyte assay	Reported cell-number multiples versus control: GHK 260-fold, GHK-Cu 320-fold, Ac-GHK-Arg-NH2 360-fold	As stated in the patent; assay normalization and duration are insufficiently clear for clinical interpretation
Epithalon-related laboratory summary	41.2% for modified peptide versus 33.3% for parent	The text combines telomerase activity and telomere elongation rather than clearly separating the endpoints
Cortagen-related Ki-67	Approximately threefold expression-area increase for modified peptide versus more than twofold for parent at different stated concentrations	Different tested exposures prevent a simple potency ratio
Storage and chemical stability	Modified compounds described as more stable in comparison assays	Individual stability-table values not transcribed; no human half-life established

In-vitro findings, unclear units and very large proliferation claims require independent verification. Modified analogues are not the parent peptides, and no human regeneration or longevity effect follows.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting: Patent laboratory comparisons of modified versus parent peptides; no verified human treatment cohort.
Source reviewed: Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.

Study limitations

Ac-GHK-Arg-NH2 and the corresponding modified AEDG, Semax, Selank and Cortagen constructs are different molecules from their parents. The EP and WO publications are one family, not independent studies.
In-vitro findings, unclear units and very large proliferation claims require independent verification. Modified analogues are not the parent peptides, and no human regeneration or longevity effect follows.
Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

2025 · Selank: 2025 pancreatic-injury patent — RU2833679C1Histology: Purulent inflammatory changes were absent in the treated tissue examples; stromal inflammatory proliferation and islet sclerosis were reduced

2025Patent / reported experimentsFull text available

Selank: 2025 pancreatic-injury patent — RU2833679C1

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Николай Алексеевич Смирнов, Александр Леонидович Хохлов, Елена Игоревна Самарина, Сергей Владимирович Куликов, Владимир Николаевич Федоров, Татьяна Алимовна Зубова · RU2833679C1 · patent family RU2833679C1

The patent describes less pancreatic inflammation and structural damage during Selank treatment.

Results and tables

Reported patent results

Narrative findings; numerical extraction incomplete

The patent describes less pancreatic inflammation and structural damage during Selank treatment.

Selank preclinical pancreatic-injury experiments in rats; tissue histology and biochemical outcomes, not autoimmune or human pancreatic disease.

Results · Description: pancreatic histology and stereometry, Figures 5–7.
Measure	Result	Comparison, timing and statistics
Histology	Purulent inflammatory changes were absent in the treated tissue examples; stromal inflammatory proliferation and islet sclerosis were reduced	Rat toxic-injury models; numerical histological scores not transcribed
Islet preservation	Islet-area preservation described with both administration routes	The narrative describes similar effects; no formal equivalence analysis established

The quantitative figure values and complete group sizes were not extracted. Histological protection in toxic injury cannot establish treatment of human diabetes or autoimmune pancreatitis.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting: Selank preclinical pancreatic-injury experiments in rats; tissue histology and biochemical outcomes, not autoimmune or human pancreatic disease.
Source reviewed: Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.

Study limitations

Toxic injury in rats does not establish treatment of diabetes, autoimmune pancreatitis or human pancreatic disease.
The quantitative figure values and complete group sizes were not extracted. Histological protection in toxic injury cannot establish treatment of human diabetes or autoimmune pancreatitis.
Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

2019 · Selank: adjunctive chronic-dermatosis method — RU2709534C1Psoriasis case: PASI 13 → 1; Beck depression 12 → 5; Hamilton anxiety 17 → 7

2019Patent / reported experimentsFull text available

Selank: adjunctive chronic-dermatosis method — RU2709534C1

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Луиза Афгатовна Юсупова, Евгения Владимировна Бильдюк · RU2709534C1 · patent family 69006604

The patent reports reductions in skin-severity and psychological scores, alongside standard topical treatment.

Results and tables

Reported patent results

Reported findings

The patent reports reductions in skin-severity and psychological scores, alongside standard topical treatment.

Three illustrated dermatosis cases receiving topical hydrocortisone plus adjunctive Selank; no adequately documented randomized comparison.

Results · Description: clinical Examples 1–3 and concluding effectiveness statement.
Measure	Result	Comparison, timing and statistics
Psoriasis case	PASI 13 → 1; Beck depression 12 → 5; Hamilton anxiety 17 → 7	Single-patient before/after findings · Skin findings described through day 15
Eczema case	EASI 9 → 1; Beck depression 11 → 4	Single-patient before/after findings · Skin findings described through day 16
Atopic dermatitis case	SCORAD 23 → 9	Single-patient before/after finding · Skin findings described through day 13
Comparative effectiveness statement	The text claims 87.6% clinical improvement, but does not provide a usable group denominator or a clear comparative effect calculation	This percentage is not entered as a verified treatment effect

Concurrent steroid treatment, selected cases and incomplete comparator reporting prevent attribution to Selank. The source has a mg/µg dosing inconsistency; no regimen is reproduced.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting: Three illustrated dermatosis cases receiving topical hydrocortisone plus adjunctive Selank; no adequately documented randomized comparison.
Source reviewed: Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.

Study limitations

Concurrent care prevents simple attribution; the document also contains a dose-unit inconsistency, so no administration regimen is reproduced here.
Concurrent steroid treatment, selected cases and incomplete comparator reporting prevent attribution to Selank. The source has a mg/µg dosing inconsistency; no regimen is reproduced.
Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

2019 · RU2709503C1: Selank in acute cold-water hypothermia models — RU2709503C1Free swimming · Example 1: 23% longer active swimming than saline

2019Patent / reported experimentsFull text available

RU2709503C1: Selank in acute cold-water hypothermia models — RU2709503C1

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

L. A. Andreeva, V. P. Vdovichenko, E. A. Nemersky, A. Yu. Petrovskaya, A. K. Petrovsky, N. A. Smirnov, V. N. Fedorov, T. B. Fedorova · RU2709503C1 · patent family 69006996

Applicant claims use of Selank for resistance to acute cooling, with separate rat swimming and survival examples.

Results and tables

Reported patent results

Reported findings

Applicant claims use of Selank for resistance to acute cooling, with separate rat swimming and survival examples.

20 rats in free swimming and 36 in a separate 60-minute 9°C flotation-collar model. Intranasal Selank 200 µg/kg, timing varied by arm.

Results · Original patent, selected methods and examples checked
Measure	Result	Comparison, timing and statistics
Free swimming · Example 1	23% longer active swimming than saline	10 rats per arm at 9°C; reported p<0.05.
Post-exposure arm · Example 2	40% survived the subsequent observation period	Only 25% of saline controls survived the first hour and all died by day 2. Patent reports a 3.2-fold first-hour survival comparison.
Pre- and post-exposure schedule	No reported improvement in final survival	Distinct from the post-exposure-only arm.

Animal patent experiments. Human treatment of hypothermia is outside the evidence.

Source for these results ↗ · Reviewed 2026-11-09

Population / setting: 20 rats in free swimming and 36 in a separate 60-minute 9°C flotation-collar model. Intranasal Selank 200 µg/kg, timing varied by arm.
Source reviewed: Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.

Study limitations

Animal patent experiments. Human treatment of hypothermia is outside the evidence.
Animal patent experiments. Human treatment of hypothermia is outside the evidence.
Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-09.

Read the source ↗

2011 · Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank

2011Animal / experimentalEnglish abstract

Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank

Kolomin T, Shadrina M, Andreeva L, Slominsky P, Limborska S, Myasoedov N · Regulatory peptides

Of 84 inflammation-related genes assessed, 34 changed across the peptide experiments; Bcl6-related responses were prominent.

Population / setting: Mouse spleen gene-expression experiments with Selank and two fragments
Source reviewed: Original publication abstract checked; full methodological appraisal pending.

Study limitations

The 34-gene total spans Selank and fragment experiments.
Gene-expression responses do not establish treatment of human autoimmune disease.

Reviewed 2026-11-05.

Read the source ↗

2013 · Selank in rat and primate fatigue modelsRats: The abstract reports a short-lived change in fatigue-like behavior after Selank.

2013Animal / experimentalRussian source · see review scope

Selank in rat and primate fatigue models

T. N. Sollertinskaya; M. V. Shorokhov; N. F. Myasoedov · 6th Russian Symposium on Proteins and Peptides, p. 106

The abstract reports a short-lived change in fatigue-like behavior after Selank.

Results and tables

Reported findings and study design

Reported findings

Conference abstract describing behavioral, EEG, autonomic and motor assessments in an experimental fatigue model. Monkeys received repeated intranasal Selank. The abstract supplies no dose, group sizes or effect estimates.

Dose, route and schedule

Protocol source ↗ · Original source

Results · Original Russian-language source
Measure	Result	Comparison, timing and statistics
Rats	The abstract reports a short-lived change in fatigue-like behavior after Selank.
Primates	The authors reported a gradual increase in task performance and changes in EEG after repeated intranasal dosing.

The authors modeled selected fatigue-like features in animals. The experiment did not enroll people or validate an ME/CFS model.

Source for these results ↗ · Reviewed 2026-11-12

Population / setting: Rats and monkeys exposed to experimental stressors
Source reviewed: Conference abstract describing behavioral, EEG, autonomic and motor assessments in an experimental fatigue model. Monkeys received repeated intranasal Selank. The abstract supplies no dose, group sizes or effect estimates.

Study limitations

The authors modeled selected fatigue-like features in animals. The experiment did not enroll people or validate an ME/CFS model.

Reviewed 2026-11-12.

Read the source ↗

2022 · Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats.Total withdrawal index reduction: 39.6% Selank versus 49.3% diazepam

2022Animal / experimentalEnglish abstract

Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats.

Konstantinopolsky MA, Chernyakova IV, Kolik LG · Bulletin of experimental biology and medicine

Results and tables

Reported findings and study design

Rat morphine-withdrawal model; single IP Selank 0.3 mg/kg versus diazepam 2 mg/kg.

Dose, route and schedule

Single intraperitoneal Selank dose of 0.3 mg/kg; diazepam comparator 2 mg/kg.

Protocol source ↗ · Indexed abstract

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
Measure	Result	Comparison, timing and statistics
Total withdrawal index reduction	39.6% Selank versus 49.3% diazepam
Tactile sensitivity threshold	Ninefold versus thirteenfold increase
Convulsions, ptosis and posture disorders	Attenuation reported with Selank	p<0.0001

Animal dependence model; no human withdrawal regimen or efficacy is established.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting: Rats with naloxone-triggered morphine withdrawal
Source reviewed: Publication metadata and indexed abstract checked through Europe PMC on 28 October 2026; full text not appraised.

Study limitations

Animal and laboratory findings do not establish benefit in people.
Abstract only. Full methods, sample-size details and adverse-event tables were outside the review.

Reviewed 2026-10-28.

Read the source ↗

2020 · Morphological Changes in the Large Intestine of Rats Subjected to Chronic Restraint Stress and Treated with Selank.Corticosterone and colon-wall injury: Reductions reported

2020Animal / experimentalEnglish abstract

Morphological Changes in the Large Intestine of Rats Subjected to Chronic Restraint Stress and Treated with Selank.

Mukhina AY, Mishina ES, Bobyntsev II, Medvedeva OA, Svishcheva MV, Kalutskii PV, Andreeva LA, Myasoedov NF · Bulletin of experimental biology and medicine

Selank-treated rats had lower corticosterone and fewer stress-related changes in the colon wall. The study connects stress biology with tissue changes in the gut.

Results and tables

Reported findings and study design

Male Wistar rats with restraint stress; IP Selank 80, 250 or 750 micrograms/kg 15 minutes before exposure.

Dose, route and schedule

Intraperitoneal doses of 80, 250 or 750 micrograms/kg, 15 minutes before stress exposure.

Protocol source ↗ · Indexed abstract

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
Measure	Result	Comparison, timing and statistics
Corticosterone and colon-wall injury	Reductions reported	No numerical concentration, injury score or sample size supplied

Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting: Male Wistar rats exposed to restraint stress
Source reviewed: Publication metadata and indexed abstract checked through Europe PMC on 28 October 2026; full text not appraised.

Study limitations

Animal and laboratory findings do not establish benefit in people.
Abstract only. Full methods, sample-size details and adverse-event tables were outside the review.

Reviewed 2026-10-28.

Read the source ↗

2019 · Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats.Object recognition in non-ethanol nine-month-old rats: Improvement reported

2019Animal / experimentalEnglish abstract

Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats.

Kolik LG, Nadorova AV, Antipova TA, Kruglov SV, Kudrin VS, Durnev AD · Bulletin of experimental biology and medicine

Results and tables

Reported findings and study design

Rats exposed to 10% ethanol as sole fluid for 30 weeks; Selank 0.3 mg/kg/day IP for seven days. Object-recognition test and ex-vivo BDNF assays.

Dose, route and schedule

0.3 mg/kg/day intraperitoneally for seven days.

Protocol source ↗ · Indexed abstract

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
Measure	Result	Comparison, timing and statistics
Object recognition in non-ethanol nine-month-old rats	Improvement reported	p<0.05
Ethanol-withdrawal memory/attention disturbances	Prevention reported	p<0.01
Ethanol-associated BDNF increase	Prevented in hippocampus and frontal cortex	p<0.05

No numerical behavioral effect size is supplied. This is normalization of an ethanol-associated BDNF increase, not a claim that Selank universally raises BDNF.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting: Rats exposed to 10% ethanol as their only fluid for 30 weeks
Source reviewed: Publication metadata and indexed abstract checked through Europe PMC on 28 October 2026; full text not appraised.

Study limitations

Animal and laboratory findings do not establish benefit in people.
Abstract only. Full methods, sample-size details and adverse-event tables were outside the review.

Reviewed 2026-10-28.

Read the source ↗

2019 · Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress.Degenerative liver changes: Reduced at all three doses

2019Animal / experimentalEnglish abstract

Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress.

Fomenko EV, Bobyntsev II, Ivanov AV, Belykh AE, Andreeva LA, Myasoedov NF · Bulletin of experimental biology and medicine

Selank reduced stress-related liver-cell damage at all tested doses. The strongest reported effect occurred at the middle dose, 300 micrograms/kg; the response was not simply greater at higher doses.

Results and tables

Reported findings and study design

Male Wistar rats with foot-shock stress; IP Selank 100, 300 or 1,000 micrograms/kg 15 minutes before each session.

Dose, route and schedule

100, 300 or 1,000 micrograms/kg intraperitoneally, 15 minutes before each stress session.

Protocol source ↗ · Indexed abstract

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
Measure	Result	Comparison, timing and statistics
Degenerative liver changes	Reduced at all three doses
Nucleus/cytoplasm ratio	Restored at 300 and 1,000 micrograms/kg
Strongest reported stress-limiting effect	300 micrograms/kg	Middle tested dose; no numerical histology effect size supplied

Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting: Male Wistar rats under chronic foot-shock stress
Source reviewed: Publication metadata and indexed abstract checked through Europe PMC on 28 October 2026; full text not appraised.

Study limitations

Animal and laboratory findings do not establish benefit in people.
Abstract only. Full methods, sample-size details and adverse-event tables were outside the review.

Reviewed 2026-10-28.

Read the source ↗

2019 · State of Colon Microbiota in Rats during Chronic Restraint Stress and Selank Treatment.Gut microbiota: Restoration reported

2019Animal / experimentalEnglish abstract

State of Colon Microbiota in Rats during Chronic Restraint Stress and Selank Treatment.

Mukhina AY, Medvedeva OA, Svishcheva MV, Shevchenko AV, Efremova NN, Bobyntsev II, Kalutskii PV, Andreeva LA, Myasoedov NF · Bulletin of experimental biology and medicine

Results and tables

Reported findings and study design

Male Wistar rats with chronic restraint stress; IP Selank 80, 250 or 750 micrograms/kg 15 minutes before exposure.

Dose, route and schedule

80, 250 or 750 micrograms/kg intraperitoneally, 15 minutes before stress exposure.

Protocol source ↗ · Indexed abstract

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
Measure	Result	Comparison, timing and statistics
Gut microbiota	Restoration reported	No bacterial abundance percentages or species-level effect sizes in the abstract

Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting: Male Wistar rats under chronic restraint stress
Source reviewed: Publication metadata and indexed abstract checked through Europe PMC on 28 October 2026; full text not appraised.

Study limitations

Animal and laboratory findings do not establish benefit in people.
Abstract only. Full methods, sample-size details and adverse-event tables were outside the review.

Reviewed 2026-10-28.

Read the source ↗

2026 · Transcriptomic Effects of Peptide Drug Selank during Early Experimental Cerebral Ischemia in RatsDifferentially expressed genes: 118

2026Animal / experimentalFull text available

Transcriptomic Effects of Peptide Drug Selank during Early Experimental Cerebral Ischemia in Rats

I. B. Filippenkov, Ya. Yu. Shpetko, V. V. Stavchansky, A. E. Denisova, L. V. Gubsky, L. A. Andreeva, N. F. Myasoedov, S. A. Limborska, L. V. Dergunova · Molecular Biology. 2026;60:530–542.

At 4.5 hours after arterial occlusion, Selank was associated with 118 differentially expressed genes; 99 were downregulated. Several ischemia-associated immune-expression changes were partly reversed.

Results and tables

Reported findings and study design

Three rat groups, five per group; RNA sequencing three per group. Selank 300 micrograms/kg IP at 90 minutes and 2.5 hours after arterial occlusion; tissue at 4.5 hours.

Dose, route and schedule

300 micrograms/kg intraperitoneally at 90 minutes and 2.5 hours after occlusion began. Tissue was collected at 4.5 hours. Experimental animal regimen.

Protocol source ↗ · Publisher methods

Results · Previously reviewed publisher full-text methods and results
Measure	Result	Comparison, timing and statistics
Differentially expressed genes	118
Downregulated genes	99	Subset of the 118 differentially expressed genes
Endpoint timing	4.5 hours after occlusion	Early molecular endpoint, not a functional recovery assessment

Uses the previously reviewed publisher methods/results; related program datasets may overlap.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting: Three groups of five rats; RNA sequencing used three animals per group
Source reviewed: Publisher full-text methods and results checked; no independent reanalysis.

Study limitations

Early molecular endpoints do not establish functional recovery or human stroke benefit.
Small RNA-sequencing groups; related program datasets must be checked before treating reports as independent replication.

Reviewed 2026-10-11.

Read the source ↗

2025 · Psychosomatic features of anxiety and depressive disorders

2025Uncontrolled human reportEnglish abstract

Psychosomatic features of anxiety and depressive disorders

V. A. Verbenko, A. A. Dvirsky, A. A. Soldatenko · Vrach. 2025;36(2):5–12.

The authors report improvement in anxiety-related and somatic symptoms during Selank treatment. The accessible publisher abstract does not quantify a controlled treatment effect.

Population / setting: Patients with anxiety/depressive and somatic symptoms; original full-text methods await retrieval
Source reviewed: Publisher metadata and abstract checked; full paper not retrieved.

Study limitations

Publisher abstract lacks sufficient allocation, comparator and numerical outcome detail for a causal conclusion.
Full PDF retrieval was unsuccessful; search-indexed methods fragments are not treated as a full-text review.

Reviewed 2026-10-08.

Read the source ↗

2005 · Natural and hybrid ("chimeric") stable regulatory glyproline peptides.

2005ReviewEnglish abstract

Natural and hybrid ("chimeric") stable regulatory glyproline peptides.

Ashmarin IP, Samonina GE, Lyapina LA, Kamenskii AA, Levitskaya NG, Grivennikov IA, Dolotov OV, Andreeva LA, Myasoedov NF · Pathophysiology : the official journal of the International Society for Pathophysiology

The developers described PGP-containing hybrid peptides as a way to combine regulatory activity with greater peptide stability. This historical framework does not transfer Semax or Selank outcomes to isolated PGP.

Population / setting: Developer synthesis of glyprolin research
Source reviewed: Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.

Study limitations

Review of a research program, not an independent trial.
Specific peptide origin, metabolism and clinical claims require original-source confirmation.

Reviewed 2026-10-05.

Read the source ↗

2015 · Optimization of the treatment of anxiety disorders with selankAnxiety improvement: Earlier with add-on Selank

2015Human comparative studyEnglish abstract

Optimization of the treatment of anxiety disorders with selank

Format: Journal article · Reviewed: Abstract

V. E. Medvedev, O. N. Tereshchenko, N. V. Kost, A. Y. Ter-Israelyan, E. V. Gushanskaya, I. K. Chobanu, O. Y. Sokolov, N. F. Myasoedov · Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(6):33–40

The authors report earlier symptom improvement and fewer unwanted effects with adjunctive Selank. Both groups received phenazepam.

Results and tables

Reported findings and study design

70 patients: phenazepam alone 30 versus phenazepam plus Selank 40.

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
Measure	Result	Comparison, timing and statistics
Anxiety improvement	Earlier with add-on Selank	No numerical magnitude reported
Sedation and other adverse symptoms	Fewer reported with the combination	Event counts not supplied

Both groups received phenazepam. This comparison does not isolate Selank monotherapy.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting: 70 patients: 40 Selank plus phenazepam; 30 phenazepam alone
Source reviewed: Indexed abstract checked; allocation, blinding and full outcome tables not reviewed.

Study limitations

Does not isolate Selank monotherapy.
Allocation and blinding unresolved; a combination comparison is not general evidence of safety.

Reviewed 2026-10-02.

Read the source ↗

2020 · Functional Connectomic Approach to Studying Selank and Semax EffectsFunctional connectivity: Between-group and between-condition differences involving right amygdala and right temporal regions

2020Human comparative studyEnglish abstract

Functional Connectomic Approach to Studying Selank and Semax Effects

Original Semax / Selank research preparations; no equivalence to modified commercial analogues asserted · Journal publication

Ya R Panikratova, I S Lebedeva, O Yu Sokolov, A D Rumshiskaya, D A Kupriyanov, N V Kost, N F Myasoedov · Dokl Biol Sci. 490(1):9–11

A 52-person fMRI study found drug-related differences in amygdala–temporal connectivity after Semax, Selank or placebo; it did not quantify improved anxiety or cognition.

Results and tables

Reported findings and study design

A 52-person fMRI study found drug-related differences in amygdala–temporal connectivity after Semax, Selank or placebo; it did not quantify improved anxiety or cognition.

52 healthy participants; resting-state fMRI before treatment and at 5 and 20 minutes.

Results · Primary-publication indexed abstract; no full-text table appraisal
Measure	Result	Comparison, timing and statistics
Functional connectivity	Between-group and between-condition differences involving right amygdala and right temporal regions	Brain-imaging finding; no clinical symptom response rates
Participants	52 across Semax, Selank and placebo	Arm counts not supplied in indexed abstract
Assessment schedule	Baseline; 5 and 20 minutes

Connectivity changes are not proof of improved executive function or treatment of anxiety. No numerical clinical effect is available in this abstract.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting: 52 healthy participants; separate Semax, Selank and placebo conditions
Source reviewed: Indexed citation and English abstract checked; full methods and risk of bias not appraised.

Study limitations

This compares separate interventions; it is not a Semax-plus-Selank combination trial.
No demonstrated cognitive-performance gain follows from the imaging endpoint.
Potential overlap with earlier imaging publications remains to be checked.

Reviewed 2026-11-01.

Read the source ↗

2008 · Efficacy and possible mechanisms of action of Selank in generalized anxiety disorders and neurastheniaAnxiety outcome: Similar changes reported

2008Randomized trialEnglish abstract

Efficacy and possible mechanisms of action of Selank in generalized anxiety disorders and neurasthenia

Original Semax / Selank research preparations; no equivalence to modified commercial analogues asserted · Journal publication

Format: Indexed abstract plus abridged commercial-hosted reprint · Reviewed: Abstract and selected reprint methods; source discrepancy

A A Zozulia, G G Neznamov, T S Siuniakov, N V Kost, M V Gabaeva, O Iu Sokolov, E V Serebriakova, O A Siranchieva, A V Andriushenko, E S Telesheva, S A Siuniakov, A B Smulevich, N F Miasoedov, S B Seredenin · Zh Nevrol Psikhiatr Im S S Korsakova. 108(4):38–48

The authors report similar anxiety changes with the two treatments and assess serum enkephalin metabolism.

Results and tables

Reported findings and study design

62 patients with generalized anxiety disorder or neurasthenia. Indexed abstract: Selank 30, medazepam 32.

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
Measure	Result	Comparison, timing and statistics
Anxiety outcome	Similar changes reported	No numerical scale change supplied
Treatment-arm counts in an abridged reprint	42 and 20	Conflicts with the indexed 30/32 split

The arm discrepancy is unresolved. The figures describe diagnostic groups. Treatment-group sizes are separate.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting: 62 patients; treatment-arm counts conflict between indexed abstract (30/32) and abridged reprint (42/20)
Source reviewed: Indexed abstract and branded-site abridged PDF methods checked. The PDF explicitly states it is shortened; it is not the complete original article.

Study limitations

Original journal version needed to resolve treatment-arm discrepancy. The 30 anxiety and 32 neurasthenia cases are diagnostic groups. Treatment-group sizes are separate.
Allocation concealment and blinding remain unresolved.
Active-comparator similarity does not establish noninferiority or long-term safety.

Reviewed 2026-10-02.

Read the source ↗

2014 · A comparison of the anxiolytic effect and tolerability of Selank and phenazepam in anxiety disordersPersistence of anxiolytic effect: One week after the final dose

2014Human comparative studyEnglish abstract

A comparison of the anxiolytic effect and tolerability of Selank and phenazepam in anxiety disorders

Original Semax / Selank research preparations; no equivalence to modified commercial analogues asserted · Journal publication

V E Medvedev, O N Tereshchenko, A Iu Israelian, I K Chobanu, N V Kost, O Iu Sokolov, N F Miasoedov · Zh Nevrol Psikhiatr Im S S Korsakova. 114(7):17–22

An active-comparator report describes anxiety and quality-of-life changes.

Results and tables

Reported findings and study design

60 patients with anxiety/phobic or somatoform disorders; Selank versus phenazepam.

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
Measure	Result	Comparison, timing and statistics
Persistence of anxiolytic effect	One week after the final dose	Absolute change and confidence interval absent from the abstract

Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting: 60 patients with anxiety/phobic or somatoform disorders
Source reviewed: Indexed citation and English abstract checked; full methods and risk of bias not appraised.

Study limitations

Random allocation and blinding are not established from the abstract.
Short follow-up and a small comparison cannot establish long-term safety or general cognitive enhancement.

Reviewed 2026-09-30.

Read the source ↗

2001 · Semax and Selank inhibit enkephalin-degrading enzymes from human serumSemax IC50: 10 microM

2001In vitroEnglish abstract

Semax and Selank inhibit enkephalin-degrading enzymes from human serum

Original Semax / Selank research preparations; no equivalence to modified commercial analogues asserted · Journal publication

N V Kost, O Iu Sokolov, M V Gabaeva, I A Grivennikov, L A Andreeva, N F Miasoedov, A A Zozulia · Bioorg Khim. 27(3):180–183

Both peptides and certain fragments inhibited peptide-degrading enzymes in laboratory assays.

Results and tables

Reported findings and study design

Human-serum enzyme assays comparing Semax, Selank and peptide-degradation inhibitors.

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
Measure	Result	Comparison, timing and statistics
Semax IC50	10 microM
Selank IC50	20 microM
Puromycin comparator IC50	10 mM
Active fragments	Five-amino-acid fragments inhibited degradation; three/four/six-amino-acid fragments did not

IC50 values measure enzyme inhibition in vitro, not clinical potency or dose equivalence.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting: Human-serum enzyme assays
Source reviewed: Indexed citation and English abstract checked; full methods and risk of bias not appraised.

Study limitations

Human-derived serum does not make this a patient trial.
Assay concentrations and enzyme effects do not establish a clinical mechanism or benefit.

Reviewed 2026-09-30.

Read the source ↗

2003 · Selank and short peptides of the tuftsin family in regulation of adaptive behavior in stress

2003Animal / experimentalEnglish abstract

Selank and short peptides of the tuftsin family in regulation of adaptive behavior in stress

Original Semax / Selank research preparations; no equivalence to modified commercial analogues asserted · Journal publication

M M Kozlovskaya, I I Kozlovskii, E A Valdman, S B Seredenin · Neurosci Behav Physiol. 33(9):853–860

The experiments compare behavior across structurally related peptides and emotional-reactivity groups.

Population / setting: Rat and mouse conflict-stress models; tuftsin-family peptides and fragments
Source reviewed: Indexed citation and English abstract checked; full methods and risk of bias not appraised.

Study limitations

Animal adaptation findings do not establish protection during human occupational stress.
The 2002 Russian citation and this 2003 English record should not be counted as independent replications without comparison.

Reviewed 2026-09-30.

Read the source ↗

2016 · Selank Administration Affects the Expression of Some Genes Involved in GABAergic NeurotransmissionChanged genes at one hour: 45

2016Animal / experimentalFull text available

Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission

Original Semax / Selank research preparations; no equivalence to modified commercial analogues asserted · Journal publication

Anastasiya Volkova, Maria Shadrina, Timur Kolomin, Lyudmila Andreeva, Svetlana Limborska, Nikolay Myasoedov, Petr Slominsky · Front Pharmacol. 7:31

The study reports changes in neurotransmission-related gene expression after Selank.

Results and tables

Reported findings and study design

Rat frontal-cortex PCR panel of 84 neurotransmission genes; Selank or GABA 300 micrograms/kg; assessments at one and three hours.

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
Measure	Result	Comparison, timing and statistics
Changed genes at one hour	45
Changed genes at three hours	22
Drug-response correlation	Positive at one hour	No numerical coefficient supplied

The counts describe the assay’s reported gene-expression changes; they are not a count of beneficial mechanisms.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting: 30 male Wistar rats; Selank, GABA and control groups; frontal-cortex gene-expression assays
Source reviewed: Publisher text: identity, animal methods and scope checked. Full independent analysis not completed.

Study limitations

Samples were pooled by group and time point; this limits inference about individual variability.
Gene-expression similarity does not demonstrate a benzodiazepine-equivalent clinical action.

Reviewed 2026-09-30.

Read the source ↗

2018 · Peptide-based Anxiolytics: Molecular Aspects of Heptapeptide Selank Biological Activity

2018In vitroEnglish abstract

Peptide-based Anxiolytics: Molecular Aspects of Heptapeptide Selank Biological Activity

Original Semax / Selank research preparations; no equivalence to modified commercial analogues asserted · Journal publication

Tatiana V Vyunova, Lioudmila Andreeva, Konstantin Shevchenko, Nikolay Myasoedov · Curr Mol Pharmacol. PMID 30255741

The authors examine GABA-binding modulation as a possible mechanistic explanation.

Population / setting: Radioligand binding and isolated brain-cell membrane assays
Source reviewed: Indexed citation and English abstract checked; full methods and risk of bias not appraised.

Study limitations

Receptor-binding results are laboratory evidence, not proof of clinical efficacy.
Interactions in an assay do not establish safe combinations with other drugs.

Reviewed 2026-09-30.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Browse bibliography & PDFs ↗

SelankСеланк

What the studies found

Anxiety improvements reported against an active comparator

Selank in rat and primate fatigue models

A comparison of the anxiolytic effect and tolerability of Selank and phenazepam in anxiety disorders

About Selank

Names in this research collection

Pregnancy and offspring research

More study findings

Semax and Selank in acute loaded swimming

Rat behavioral assays: selank

Use of Selank to correct measures of integrative brain activity and biogenic amine levels in adult rats resulting from antenatal hypoxia

Studying the Toxic Effects of Some Biologically Active Peptides on the Model of Mouse Embryonic Stem Cells

Optimization of the treatment of anxiety disorders with selank

Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats.

Morphological Changes in the Large Intestine of Rats Subjected to Chronic Restraint Stress and Treated with Selank.

Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats.

Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress.

State of Colon Microbiota in Rats during Chronic Restraint Stress and Selank Treatment.

Understanding the evidence

Connections in the research

Glyprolins & PGP hybrids ↗

What remains unclear

Additional clinical comparison and source discrepancy added

What remains unresolved

Selank: from tuftsin to stress research.

Clinical anxiety comparisons

Stress and tuftsin-family research

Enkephalin, GABA and neurotrophins

Imaging and open research branches

Lineage and document recovery

Selank as a modulator of GABAergic, neuroreception and signaling gene expression

Intranasal Selank and hippocampal BDNF expression in rats

Selank GABA-related gene-expression paper — publisher PDF

Early tuftsin-analogue / Selank precursor work

Serotonergic contribution to synthetic-tuftsin-analogue anxiolysis

Selank gene expression in brain and spleen

Anti-ulcer effects of Selank and its fragments

Clinical pharmacology of Selank — dissertation lead

Patents and claimed inventions

Linked sources

Reported findings and study design

Dose, route and schedule

Reported findings and study design

Dose, route and schedule

Reported findings and study design

Reported findings and study design

Reported patent results

Reported patent results

Reported patent results

Reported patent results

Reported findings and study design

Dose, route and schedule

Reported findings and study design

Dose, route and schedule

Reported findings and study design

Dose, route and schedule

Reported findings and study design

Dose, route and schedule

Reported findings and study design

Dose, route and schedule

Reported findings and study design

Dose, route and schedule

Reported findings and study design

Dose, route and schedule

Reported findings and study design

Reported findings and study design

Reported findings and study design

Reported findings and study design

Reported findings and study design

Reported findings and study design

Related compound research

Semax research ↗

Cortagen research ↗

Glyprolins & PGP hybrids research ↗

Cerebrolysin research ↗